These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1364 related items for PubMed ID: 19162288

  • 21. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
    Gomez AM, Van Den Broeck J, Vrolix K, Janssen SP, Lemmens MA, Van Der Esch E, Duimel H, Frederik P, Molenaar PC, Martínez-Martínez P, De Baets MH, Losen M.
    Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
    [Abstract] [Full Text] [Related]

  • 22. Association of neonatal myasthenia gravis with antibodies against the fetal acetylcholine receptor.
    Vernet-der Garabedian B, Lacokova M, Eymard B, Morel E, Faltin M, Zajac J, Sadovsky O, Dommergues M, Tripon P, Bach JF.
    J Clin Invest; 1994 Aug; 94(2):555-9. PubMed ID: 8040310
    [Abstract] [Full Text] [Related]

  • 23. Myasthenia gravis and myasthenic syndromes.
    Engel AG.
    Ann Neurol; 1984 Nov; 16(5):519-34. PubMed ID: 6095730
    [Abstract] [Full Text] [Related]

  • 24. [Clinical correlation of anti-receptor antibody titer, sensitivity to curare and electromyographic changes in experimental autoimmune myasthenia gravis].
    Chen SM.
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1990 Oct; 23(5):293-6, 320. PubMed ID: 2282884
    [Abstract] [Full Text] [Related]

  • 25. Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis.
    Nakata R, Motomura M, Masuda T, Shiraishi H, Tokuda M, Fukuda T, Ando T, Yoshimura T, Tsujihata M, Kawakami A.
    Eur J Neurol; 2013 Sep; 20(9):1272-6. PubMed ID: 23679930
    [Abstract] [Full Text] [Related]

  • 26. Myasthenia gravis experimentally induced with muscle-specific kinase.
    Shigemoto K, Kubo S, Jie C, Hato N, Abe Y, Ueda N, Kobayashi N, Kameda K, Mominoki K, Miyazawa A, Ishigami A, Matsuda S, Maruyama N.
    Ann N Y Acad Sci; 2008 Sep; 1132():93-8. PubMed ID: 18096854
    [Abstract] [Full Text] [Related]

  • 27. [Value of acetylcholine receptor antibodies in myasthenia gravis].
    Zeitlhofer J, Maida EM, Mamoli B, Mayr N.
    Wien Med Wochenschr; 1986 Jul 15; 136(13):329-32. PubMed ID: 3765651
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Refractoriness to a second episode of experimental myasthenia gravis. Correlation with AChR concentration and morphologic appearance of the postsynaptic membrane.
    Corey AL, Richman DP, Agius MA, Wollmann RL.
    J Immunol; 1987 May 15; 138(10):3269-75. PubMed ID: 3494763
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Teratogen update: maternal myasthenia gravis as a cause of congenital arthrogryposis.
    Polizzi A, Huson SM, Vincent A.
    Teratology; 2000 Nov 15; 62(5):332-41. PubMed ID: 11029151
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.
    Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y, Tsujihata M, Vincent A, Eguchi K.
    Ann Neurol; 2005 Feb 15; 57(2):289-93. PubMed ID: 15668981
    [Abstract] [Full Text] [Related]

  • 34. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat.
    Meinl E, Klinkert WE, Wekerle H.
    Am J Pathol; 1991 Nov 15; 139(5):995-1008. PubMed ID: 1951638
    [Abstract] [Full Text] [Related]

  • 35. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors.
    Araga S, Galin FS, Kishimoto M, Adachi A, Blalock JB.
    J Immunol; 1996 Jul 01; 157(1):386-92. PubMed ID: 8683141
    [Abstract] [Full Text] [Related]

  • 36. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects.
    Viegas S, Jacobson L, Waters P, Cossins J, Jacob S, Leite MI, Webster R, Vincent A.
    Exp Neurol; 2012 Apr 01; 234(2):506-12. PubMed ID: 22326541
    [Abstract] [Full Text] [Related]

  • 37. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor.
    Loutrari H, Kokla A, Tzartos SJ.
    Eur J Immunol; 1992 Sep 01; 22(9):2449-52. PubMed ID: 1516631
    [Abstract] [Full Text] [Related]

  • 38. Anti-AChR-negative myasthenia gravis: clinical and immunological features.
    Evoli A, Bartoccioni E, Batocchi AP, Scuderi F, Tonali P.
    Clin Invest Med; 1989 Apr 01; 12(2):104-9. PubMed ID: 2706833
    [Abstract] [Full Text] [Related]

  • 39. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.
    Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Ozdemir C, Vincent A, Saruhan-Direskeneli G.
    Neurology; 2007 Feb 20; 68(8):609-11. PubMed ID: 17310034
    [Abstract] [Full Text] [Related]

  • 40. Molecular aspects of experimental autoimmune myasthenia gravis.
    Fuchs S, Bartfeld D, Mochly-Rosen D, Schmidt-Hopfeld I, Tarrab-Hazdai R.
    Prog Clin Biol Res; 1981 Feb 20; 63():405-17. PubMed ID: 7031685
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 69.